The FDA recorded a supplement on 27 August to abbreviated new drug application 078786, a generic carvedilol. The record does not state what changed; supplements to generic licences are usually manufacturing, labelling or packaging updates.
There is no safety signal or new indication in the record, and no CDSCO action is known. The urological relevance is indirect but real: carvedilol blocks alpha-1 receptors as well as beta receptors, so in older men taking it for heart failure or hypertension, adding tamsulosin, alfuzosin or another alpha-blocker for BPH increases the risk of postural hypotension and falls.
- No change to prescribing follows from this record.
- Check for carvedilol, labetalol or doxazosin before starting an alpha-blocker for BPH.
- Ask about dizziness on standing at the first review after adding an alpha-blocker.
- Advise taking the first alpha-blocker dose at bedtime.
Why it matters
A common cardiac drug quietly shares a mechanism with first-line BPH treatment.
Don't overread it
A licence supplement is not a new indication or a safety warning.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for urology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free